Donanemab, the newest, received FDA approval July 2024 for early AD (including mild cognitive impairment with supportive imaging evidence) and received UK MHRA approval in October 2024 with similar exclusion criteria proposed around the APOE carrier status. The gene discussed is APOE; the disease is Cognitive impairment.